OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00036647
Recruitment Status : Completed
First Posted : May 14, 2002
Last Update Posted : January 10, 2018
Canadian Cancer Trials Group
Information provided by:
Astellas Pharma Inc